Q4 2023 Earnings Summary
Reported on Feb 28, 2024 (After Market Close)
Pre-Earnings Price$58.26Last close (Feb 28, 2024)
Post-Earnings Price$49.90Open (Feb 29, 2024)
Price Change
$-8.36(-14.35%)
- Inari Medical operates in a massive $6 billion U.S. market for venous thromboembolism (VTE) treatments, which remains highly underpenetrated at only 6%, and the company expects robust growth to continue in 2024.
- The company is experiencing strong momentum entering 2024, with January a nice step-up from December, and anticipates multiple catalysts across all growth pillars, including new products, new markets, and international expansion, contributing to confident revenue guidance of $580 million to $595 million for 2024.
- Inari Medical is progressing towards sustained operating profitability in the first half of 2025 by focusing on operating leverage, demonstrating revenue growth outpacing operating expenses, enhancing long-term financial health.
- The company's revenue growth guidance for 2024 is 17.5% to 20.5%, which is lower than the 23% growth achieved in Q4 2023, suggesting a potential slowdown in growth.
- The company is under a DOJ investigation related to meals and consulting service payments provided to health care professionals, which could lead to legal consequences and impact its reputation.
- Increased competition in the VTE market from existing competitors and new entrants could affect Inari's market share and growth prospects. The company acknowledged factoring in competition into its guidance for 2024.
Research analysts covering NARI.